Skip to main content
SpringerLink
Log in
Book cover

Molecular Cytopathology pp 237–250Cite as

Molecular Biomarkers in Body Fluid Cytology

  • Chapter
  • First Online:

  • 946 Accesses

Part of the book series: Essentials in Cytopathology ((EICP,volume 26))

Abstract

Specimens from the serous cavities are commonly submitted to cytology. Removal of excess fluid can be both diagnostic and therapeutic, and is easily performed with minimal patient risk. Malignancy (typically metastatic adenocarcinoma) may account for up to one in five effusions, and not uncommonly presents from an occult site. It is essential to correctly identify the origin of these malignancies through proper application of ancillary testing, since initial clinical decisions and therapeutic choices often rely heavily on cytopathologic assessments.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ali SZ, Cibas ES. Serous cavity fluid and cerebrospinal fluid cytopathology. Essentials in cytopathology. New York: Springer; 2012.

    Book  Google Scholar 

  2. Bartley AN, Hamilton SR, Alsabeh R, Ambinder EP, Berman M, Collins E, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138(2):166–70.

    Article  PubMed  Google Scholar 

  3. Betz BL, Dixon CA, Weigelin HC, Knoepp SM, Rob MH. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. Cancer Cytopathol. 2013;121(9):489–99.

    Article  CAS  PubMed  Google Scholar 

  4. Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, Malatesta S, et al. Effective assessment of EGFR mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res. 2013;19(3):691–8.

    Article  CAS  PubMed  Google Scholar 

  5. Cagle PT, Sholl LM, Lindeman NI, Alsabeh R, Divaris DXG, Foulis P, et al. Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. Arch Pathol Lab Med. 2014;138(2):171–4.

    Article  PubMed  Google Scholar 

  6. Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbdt RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol. 2013;121(9):500–7.

    Article  CAS  PubMed  Google Scholar 

  7. Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations: are we there yet? Arch Pathol Lab Med. 2016;140:318–21.

    Google Scholar 

  8. Cross SE, Jin YS, Rao J, Gimzewski JK. Nanomechanical analysis of cells from cancer patients. Nat Nanotechnol. 2007;2(12):780–3.

    Article  CAS  PubMed  Google Scholar 

  9. Dabbs DJ. Diagnostic immunohistochemistry: theranostic and genomic applications. Saunders Philadelphia: Elsevier; 2010.

    Google Scholar 

  10. Dejmek A, Zendehrokh N, Tomaszewska M, Edsjo A. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality. Cancer Cytopathol. 2013;121(7):344–52.

    Article  CAS  PubMed  Google Scholar 

  11. DeMay R. The art and science of cytopathology. 2nd ed. Chicago: ASCP Press; 2012.

    Google Scholar 

  12. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(20):79–89.

    Article  CAS  PubMed  Google Scholar 

  13. Gill GW. Cytopreparation: principles and practice. Essentials in cytopathology. New York: Springer; 2013.

    Book  Google Scholar 

  14. Gossett DR, Tse HTK, Lee SA, Ying Y, Lindgren AG, Yang OO, Rao J, Clark AT, Di Carlo D. Hydrodynamic stretching of single cells for large population mechanical phenotyping. Proc Natl Acad Sci U S A. 2012;109:7630–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Granados R, Cibas ES, Fletcher JA. Cytogenetic analysis of effusions from malignant mesothelioma: a diagnostic adjunct to cytology. Acta Cytol. 1994;38(5):711–7.

    CAS  PubMed  Google Scholar 

  16. Han J, Cao S, Zhang K, Zhao G, Xin Y, Dong Q, Yan Y, Cui J. Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions. J Cardiothorac Surg. 2012;7:121–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Henderson DW, Reid G, Kao SC, van Zandwiik N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: part 1: cytology – only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive hyperplasia, and biomarkers. J Clin Pathol. 2013;66(10):847–53.

    Article  PubMed  Google Scholar 

  18. Henderson DW, Reid G, Kao SC, van Zandwiik N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: part 2: malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin 1 and microRNA. J Clin Pathol. 2013;66(10):854–961.

    Article  PubMed  Google Scholar 

  19. Hookim K, Roh MH, Willman J, Placido J, Weigelin HC, Field KL, Pang J, Betz BL, Knoepp SM. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer Cytopathol. 2012;121(1):52–61.

    Article  Google Scholar 

  20. Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2013;137(5):647–67.

    Article  PubMed  Google Scholar 

  21. Huss J, Conrad R, Hirschowitz S, Moatamed N. Pleural fluid metastases of salivary duct carcinoma: a case report and review of the literature. CytoJournal. 2014 Feb 15;11:4.

    Google Scholar 

  22. Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand M. Molecular changes in mesothelioma with an impact on prognosis. Arch Pathol Lab Med. 2012;126:277–93.

    Article  Google Scholar 

  23. Kawahara A, Taira T, Abe H, Watari K, Murakami Y, Fukumitsu C. Fixation effect of SurePatho preservative fluids using epidermal growth factor receptor mutation-specific antibodies for immunocytochemistry. Cancer Cytopathol. 2014;122(2):145–52.

    Article  CAS  PubMed  Google Scholar 

  24. Killian JK, Walker RL, Suuriniemi M, Jones L, Scurci S, Singh P, Cornelison R, Harmon S, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12(6):739–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006;95(10):1390–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Li J, Bao QL, Wang Y, Hu YM, Chen P. Diagnostic value of the FHIT and p16 mRNA loss and the K-ras gene mutation in pleural fluids for malignant pleural effusion. Cancer Biomark. 2013;13(1):49–58.

    PubMed  Google Scholar 

  27. Lin I, Tsai Y, Kang C, Huang W, Wang C, Lin M, et al. BMVC test, an improved fluorescent assay for detection of malignant pleural effusions. Cancer Med. 2014 Feb;3(1):162–73.

    Google Scholar 

  28. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137(6):828–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Liu X, Lu Y, Ahu G, Lei Y, Zheng L, Qin H, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013;66(12):1065–9.

    Article  PubMed  PubMed Central  Google Scholar 

  30. McMillan R, Zauderer M, Bott M, Ladanyi M. Important recent insights into the genetics and biology of malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1(4):462–85.

    PubMed  PubMed Central  Google Scholar 

  31. Moreira AL, Hasanovic A. Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens. Acta Cytol. 2012;56(6):603–10.

    Article  CAS  PubMed  Google Scholar 

  32. Murakami H, Mizuno T, Taniguchi T, et al. LATS2 is a tumor suppressor gene of malignant melanoma. Cancer Res. 2011;71:873–83.

    Article  CAS  PubMed  Google Scholar 

  33. Ordonez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Human Pathol. 2013;44(1):1–19.

    Article  CAS  Google Scholar 

  34. Pass HI. Biomarkers and prognostic factors for mesothelioma. Ann Cardiothorac Surg. 2012;1(4):449–56.

    PubMed  PubMed Central  Google Scholar 

  35. Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013;5(Suppl4):S397–408.

    PubMed  PubMed Central  Google Scholar 

  36. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413–9.

    Article  CAS  PubMed  Google Scholar 

  37. Tanaka H, Tone K, Hayashi A, Morimoto T, Taima K, Tanaka Y, et al. Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma. Lung Cancer. 2013;80(3):289–92.

    Article  PubMed  Google Scholar 

  38. Tse HTK, Gossett DR, Moon YS, Masaeli M, Sohsman M, Ying Y, Mislick K, Adams RP, Rao J, Di Carlo D. Quantitative diagnosis of malignant pleural effusions by single-cell mechanophenotyping. Sci Transl Med. 2013;5(212):212–63.

    Article  Google Scholar 

  39. Wolff AC, Hammond MEH, Hick DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2014;138:241–56.

    Article  PubMed  Google Scholar 

  40. Zendehrokh N, Dejmek A. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes. Mod Pathol. 2005 Feb; 18(2):189–96.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

    Rachel Conrad M.D.

  2. Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA, USA

    Christine Chow M.D. (Director of Cytopathology) & Jianyu Rao M.D. (Director of Cytopathology)

Authors
  1. Rachel Conrad M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Chow M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianyu Rao M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel Conrad M.D. .

Editor information

Editors and Affiliations

  1. Director of Molecular Cytopathology Department of Pathology, The Cleveland Clinic, Cleveland, Ohio, USA

    Bin Yang

  2. Director of Cytopathology Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, California, USA

    Jianyu Rao

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Conrad, R., Chow, C., Rao, J. (2016). Molecular Biomarkers in Body Fluid Cytology. In: Yang, B., Rao, J. (eds) Molecular Cytopathology. Essentials in Cytopathology, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-30741-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30741-1_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30739-8

  • Online ISBN: 978-3-319-30741-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation